Hi I'm pleased to present a brief video update on whats happening at MindBio.We recently reported a sustained anti-depressant response from microdosing MB220001 at 1 months and 3 months post cessation of an 8-week treatment cycle. Our women's health...

Hi We continue take-home dosing in two Phase 2B clinical trials with a third Phase 2B women's health trial recently approved for use of a microdose of a psychedelic medicine (MB22001) to treat mood symptoms in Premenstrual Syndrome and Premenstrual D...

Hi Please see release from MindBio Therapeutics below.Vancouver, British Columbia – July 8, 2024 – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6), (the “Company” or “MindBio”), a leading biopharmaceutical company in psychiatric microdosing me...

Hi We are pleased to present secondary data from MindBio's Phase 2A Microdosing Depression Trial completed earlier this year.Data from MindBio’s Phase 2A Depression trial indicates improvements in a range of secondary outcome measures following an 8-...

Hi Please see latest news release posted today from MindBio and Enveric Biosciences.Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders.M...

Hi The impact of under-representation of women in clinical trials is significant and has resulted in an over-representation of serious adverse events and side effects from prescribed medications in women.Tune into Dr Rachael Sumner, who discusses the...

Hi We are progressing this worthwhile clinical research in multiple Phase 2B trials and setting the company up for it's future. Read MoreNEWS RELEASEMINDBIO EXPLORES DUAL LISTING ON A SENIOR EXCHANGE WITH MULTIPLE PHASE 2B CLINICAL TRIALS UNDERWAY SU...

Hi Women remain under-represented in clinical trials, compared to men.A reason often cited, even in our own work, apart from the risk of pregnancy whilst taking an experimental drug, is the varying effects of the menstrual cycle on assessing how the...

Hi It was a surprising discovery in a randomized controlled trial testing microdoses of LSD (MB22001) in 80 healthy people. The data shows a statistically significant improvement in sleep, including total time of sleep and quality of sleep with some...

Hi It's a small step that's taken years in planning and persistence in gaining regulatory approvals for take home use and we are pleased to announce the first dose has been administered.It's a Phase 2B microdosing trial in patients with Major Depress...